Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), has announced that Medis QFR 3.0, a US Food and Drug Administration (FDA)-cleared software solution for coronary physiology assessment, is now available in the USA through its collaboration with Medis Medical Imaging.
“Helping hospitals access proven, innovative tools like QFR 3.0 is an important part of our mission,” said Ryan Graver, senior divisional vice president, THO. “This latest advancement from Medis aligns with the goals of many hospitals to enhance cath lab efficiency and support high-quality, patient-centered care. We are proud to be able to offer this cardiology diagnostic software solution to our customers.”
THO and Medis will showcase QFR 3.0 during the upcoming SCAI 2025 scientific sessions (1–3 May, Washington DC, USA), offering clinicians the opportunity to learn more about the technology and its role in supporting efficient, physiology-guided care in the cath lab.
Medis QFR has been validated through extensive clinical research, including over 200 peer-reviewed publications and data from more than 17,000 patients and 20,000 lesions. In 2024, QFR—quantitative flow ratio—was recommended by the European Society of Cardiology (ESC) in guidelines, reinforcing its clinical relevance and utility.
“We’re excited that US hospitals will now have access to QFR 3.0,” said Maya Barley, CEO of Medis Medical Imaging. “Our continued collaboration with Terumo Health Outcomes supports our goal of delivering solutions that simplify workflow while maintaining a strong foundation of clinical accuracy.”
“This partnership reflects our shared commitment to expand hospital access to innovative cardiovascular technologies,” said Ghada Farah, president of Terumo Interventional Systems.
